89bio — Investor Presentation (October 2020)
42 slides from 89bio's investor presentation, Oct 5, 2020
Slide 1: Powerful Science Meaningful Medicines Changing Lives
Nasdaq: ETNB Powerful Science Meaningful Medicines Changing Lives October 2020 Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of his
Slide 3: 89bio - Investment Highlights
89bio - Investment Highlights Validated in NASH demonstrating strong efficacy results, favorable safety/tolerability profile, and potential best-in-class dosing BIO89-100 has potential to be a leading DRUG FOR LIVER AND CARDIO-METABOLIC DISORDERS BIO89-100 DELIVERS ON THE PROMISE OF FGF21 FGF21 is a
Slide 4: Opportunity in NASH
Opportunity in NASH
Slide 5: BIO89-100: A Compelling Drug Candidate for NASH
ROBUST EFFIACCY RESULTS Statistically significant reductions in liver fat and in key liver markers (ALT) Majority of patients achieved a ≥30% (up to 88%) or a ≥50% (up to 71%) reduction in liver fat KEY UPCOMING MILESTONES Initiation of a Phase 2b trial as part of a potential Phase 2b/3 trial: 1H21
Slide 6: NASH is a Serious Liver Condition With Significant Co-Morbidities
NASH is a Serious Liver Condition With Significant Co-Morbidities 16.5 million cases projected to grow to 27 million cases by 2030 Expected to become the leading cause of liver transplant Co-morbidity Prevalence in NASH population Hypertriglyceridemia 83% Obesity 82% Hyperlipidemia / Dyslipidemia 72
Slide 7: FGF21 Has Potential To Be Mainstay of Therapy In NASH
FGF21 Has Potential To Be Mainstay of Therapy In NASH Endogenous metabolic hormone that regulates energy expenditure and glucose and lipid metabolism Reduces liver fat by action within liver and from periphery Impacts liver fibrosis via metabolic pathway and upregulation of adiponectin Native FGF21
Slide 8: FGF21 – Validated and Highly Differentiated Mechanism for NASH
FGF21 FGF19 FXR PPAR* THR-β GLP-1 Liver fat reduction ✔ ✔ ✔ ✔ ✔ Fibrosis improvement ✔ ✔ ✔ ✔ ? Triglyceride reduction ✔ ✔ ✔ ✔ LDL-C improvement ✔ Worsens LDL Worsens LDL ✔ HDL-C improvement ✔ ✔ Glycemic control ✔ ✔ ✔ Limited Side Effects ✔ GI effect** LDL ↑ Pruritis LDL ↑ Weight Gain Edema Drug-drug
Slide 9: FGF21 – Highly Promising Mechanism for NASH
RELATIVE Change in liver fat from PLACEBO (% reduction) FGF21 – Highly Promising Mechanism for NASH * Not placebo controlled; **No worsening of NAS (NAFLD Activity Score) Note: All data regarding third-party studies on this slide are based on third-party trials, some of which are in different stages
Slide 10: BIO89-100 Is An FGF21 Optimally Engineered for Efficacy and Long Dosing Interval
BIO89-100 Is An FGF21 Optimally Engineered To Balance Potential for Efficacy and Long Dosing Interval glycoPEG(20kD) C-terminus X Strong and flexible linker (glycoPEGylation technology) Mutations in positions 173 and 176 (glycoPEG attached at position 173) X N-terminus Position 182 FGF21 FGF21 is an
Slide 11: Extensive Pre-clinical and Early Clinical Data With BIO89-100
Extensive Pre-clinical and Early Clinical Data With BIO89-100 Reduced Hepatocyte Injury Reduced Liver Steatosis, Inflammation & Fibrosis Improved Lipid Handling* Improved Insulin Sensitivity Body Weight Reduction PRECLINICAL STUDIES DIN mouse model (10 weeks) ✔ ✔ ✔ ✔ ✔ DIN mouse model (19 weeks) ✔ ✔
Slide 12: Reduction In Steatosis, Inflammation, Fibrosis and NAS With BIO89-100 In DIN Model
Note: Obeticholic acid, 25 mg/kg tested as active control – did not separate from control in this study Scoring system: Steatosis (0-3), Inflammation (0-3), Fibrosis (0-4), NAS (0-13) - all were assessed at week 19; mean scores *** *** Reduction In Steatosis, Inflammation, Fibrosis and NAFLD Activit
Slide 13: Phase 1b/2a Results: Promising Benefit-Risk Profile with Convenient Dosing
Phase 1b/2a Results: Promising Benefit-Risk Profile with Convenient Dosing Significant benefits across key liver parameters observed across all dose groups and patient populations Up to 60% reduction in liver fat versus baseline and up to 70% versus placebo Up to 44% reduction in ALT (35 U/L decreas
Slide 14: BIO89-100-002: Trial Design
BIO89-100-002: Trial Design (n=2) 9mg Placebo (n=14) (n=4) (n=12) (n=3) (n=6) 3mg Placebo 18mg Placebo 18mg Placebo 27mg Placebo 36mg Placebo 12-week treatment duration + 4-week safety follow up Placebo (n=19) combined across cohorts for analysis (n=9) (n=3) (n=11) (n=4) (n=10) (n=3) KEY TRIAL ENDPO
Slide 15: Baseline Characteristics
Baseline Characteristics Parameter Mean or % Placebo (n=19) Pooled BIO89-100 (n=62) 3mg QW (n=6) 9mg QW (n=12) 18mg QW (n=11) 27mg QW (n=10) 18mg Q2W (n=14) 36mg Q2W (n=9) Age (years) 52.6 51.7 56.1 49.5 51.5 52.0 51.2 52.5 Male/Female 36.8% 38.7% 16.7% 50% 27.3% 20% 28.6% 88.9% Weight (kg) 93.6 93.
Slide 16: BIO89-100 Significantly Reduces Liver Fat Across All Dose Groups
Up to 43% of subjects normalized their liver fat (<5%) BIO89-100 significantly reduced liver volume up to 15% Changes in liver fat were similar between NASH and PNASH subjects BIO89-100 Significantly Reduces Liver Fat Across All Dose Groups MRI Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<
Slide 17: BIO89-100 Reduces Liver Fat in Significant Percentage of Subjects
BIO89-100 Reduces Liver Fat in Significant Percentage of Subjects MRI Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo *** *** *** *** *** *** Proportion of Subjects with ≥30% Relative Reduction in Liver Fat Placebo 0% QW 3mg 60%** 9mg 82%*** 18mg 60%** 27mg 86%*** Q2W 18m
Slide 18: Majority of Subjects Achieved ≥50% Reduction in Liver Fat
Majority of Subjects on BIO89-100 Achieved ≥50% Reduction in Liver Fat MRI Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo Proportion of Subjects with ≥50% Relative Reduction in Liver Fat Placebo 0% QW 3mg 20% 9mg 54%** 18mg 50%** 27mg 71%*** Q2W 18mg 39%** 36mg 50%** Rel
Slide 19: Substantial Reduction in Liver Fat and Liver Volume After 12 Weeks
BIO89-100 Showed Substantial Reduction in Liver Fat and Liver Volume After 12 Weeks of Treatment (Subject at 27mg QW) Liver fat (%) Parameter Baseline Liver fat 41.1% Liver volume (L) 2.2 Week 13 % Change 5.1% -87.6% 1.4 -35.4%
Slide 20: BIO89-100 Significantly Reduces ALT
BIO89-100 Significantly Reduces ALT PD Analysis Set; Pre-planned sensitivity analysis; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo *** * * *** Percent Change from Baseline at Week 13 Percent Change Over Time -30 U/L -22 U/L * *** ** * *** * * * *** *** Q2W QW Absolute change:
Slide 21: BIO89-100 has Clinically Meaningful Impact on Subjects with High ALT
BIO89-100 has Clinically Meaningful Impact on Subjects with High ALT PD Analysis Set in baseline ALT > 45 U/L (placebo n=6, pooled BIO89-100 n=22); Pre-planned sensitivity analysis; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo n=5 n=17 Change in ALT of ≥17 U/L has been correlated wi
Slide 22: BIO89-100 Significantly Reduces Triglycerides
Decrease from baseline in BIO89-100 treated subgroup with baseline TG ≥200 mg/dL TG: 33%-49% Non-HDL: 8%-29% BIO89-100 Significantly Reduces Triglycerides with Greater Benefit Observed in Subjects with High Triglycerides PD Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo;
Slide 23: Safety Overview
Safety Overview Treatment Emergent Adverse Event (TEAE) Placebo (n=18) 3mg QW (n=7) 9mg QW (n=12) 18mg QW (n=11) 27mg QW (n=10) 18mg Q2W (n=14) 36mg Q2W (n=9) TEAE Leading to Death 0 0 0 0 0 0 0 TEAE Leading to Discontinuation 0 0 0 0 1a 1b 0 Serious Adverse Event COVID 19 [Not Drug Related] 0 0 0 0
Slide 24: Treatment-Related Emergent AEs in ≥10% of Pooled BIO89-100 Group
Treatment-Related Emergent AEs in ≥ 10% of Pooled BIO89-100 Group Preferred Term n (%) Placebo (n=18) Pooled BIO89-100 (n=63) 3mg QW (n=7) 9mg QW (n=12) 18mg QW (n=11) 27mg QW (n=10) 18mg Q2W (n=14) 36mg Q2W (n=9) Increased Appetite 0.0% 15.9% 4 2 0 2 2 0 Safety Analysis Set; one placebo subject rec
Slide 25: Comparative Data Among FGF21 Analogs: Efficacy
Comparative Data Among FGF21 Analogs: Efficacy BIO89-100 (12 weeks) EFRUXIFERMIN (16 weeks*) PEGBELFERMIN (16 weeks) All Doses 27mg QW 28mg QW 50mg QW 10mg QD 20mg QW KEY EFFICACY PARAMETERS MRI-PDFF Relative reduction in fat vs. placebo (%) 47-70 70 63 71 32 20 ≥30% Responder (%) 60-88 86 84 85 56
Slide 26: Comparative Data Among FGF21 Analogs: Safety/Dosing
Comparative Data Among FGF21 Analogs: Safety (Selected AEs)/Dosing BIO89-100 (12 weeks) EFRUXIFERMIN (16 weeks) PEGBELFERMIN (16 weeks) Pooled BIO89-100 28mg QW 50mg QW 20mg QW 10mg QD SELECTED AE’s Treatment Related AEs Treatment Related AEs ≥10% Most Frequent AEs Diarrhea 9.5% 26% 53% 21% 12% Naus
Slide 27: Dosing Preference Study: >60% of T2D Patients Prefer Every Other Week
Dosing Preference Study: >60% of T2D Patients Prefer Or Strongly Prefer Every Other Week Injections 68% Prefer or Strongly Prefer 63% Prefer or Strongly Prefer Preference of Every Other Week Injections Over Daily Injections (vs. Pegbelfermin) Preference of Every Other Week Injections Over Weekly Inj
Slide 28: Opportunity in SHTG
Opportunity in SHTG
Slide 29: BIO89-100: A Compelling Drug Candidate for SHTG
BIO89-100: A Compelling Drug Candidate for SHTG SIGNIFICANT MARKET OPPORTUNITY Estimated up to 4M patients Approved drugs have limitations and do not provide broad metabolic benefits BIO89-100 IS A HIGHLY DIFFERENTIATED MOLECULE Statistically significant reductions in TGs across multiple doses in NA
Slide 30: SHTG Market Is Large with Significant Unmet Need
Diagnosis and treatment rates expected to increase in the future SHTG Market Is Large with Significant Unmet Need * 50% is based on registrational trials of Vascepa and Epanova (at 4mg/day dose) approved in SHTG LARGE PATIENT POPULATION WITH HIGH UNMET NEED AND MULTIPLE CO-MORBIDITIES Estimated up t
Slide 31: Current Therapies Reach Blockbuster Status Despite Falling Short
FISH OILS FIBRATES Vascepa (EPA) Lovaza (EPA+DHA) Tricor Reduce Hepatic Fat - - - Improve LDL-C - Worsens LDL Worsens LDL ALT - Warnings, Monitoring Required Glycemic Control - - - Tolerability/ Safety May prolong bleeding time Myopathy, Creatinine increases, DDI Current Therapies Reach Blockbuster
Slide 32: BIO89-100 Significantly Reduces Triglycerides in High-TG Subjects
Decrease from baseline in BIO89-100 treated subgroup with baseline TG ≥200 mg/dL TG: 33%-49% Non-HDL: 8%-29% BIO89-100 Significantly Reduces Triglycerides with Greater Benefit Observed in Subjects with High Triglycerides PD Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo;
Slide 33: Physicians Research Shows Strong Interest in Broad Metabolic Profile
Physicians Research Shows Strong Interest in the Broad Metabolic Profile of BIO89-100 for Their SHTG Patients 30% TG reduction as add on 50% TG reduction as monotherapy 30% TG reduction as add on Parameter Meaningful Chg. in Parameter Share* for Meaningful Change + TG Reduction Liver fat reduction 3
Slide 34: SHTG May Represent a Quicker and Less Expensive Path To Market
STUDY DESIGN Phase 2 Trial Adults with TG ≥ 500; N = ~90 Weekly and every two-week dosing for a period of 8 weeks Primary endpoint: Reduction from baseline in TG Secondary endpoints: Other lipids and liver fat (MRI-PDFF) Timing: Topline data in 2H21 Registrational Trial** Patients with TG ≥ 500 mg/d
Slide 35: Financial Position Summary
Financial Position Summary Cash, cash equivalents and short-term investments $73.9 million (as of June 30, 2020) 89bio received an aggregate of approx. $157.3 million in estimated net proceeds in 3Q20 from underwritten public offerings of common stock Debt facility for a tranched secured term loan o
Slide 36: Achievements and Milestones
Achievements and Milestones Initiation of a Phase 2b NASH trial as part of a potential Phase 2b/3 trial – 1H21 SHTG Phase 2 topline results – 2H21 Initiation of SHTG registrational trials (pending positive Phase 2 data) – 2022 ACHIEVEMENTS (~2 Years) CURRENT FOCUS MILESTONES Completed 2 clinical tri
Slide 37: 89bio - Investment Highlights
89bio - Investment Highlights Validated in NASH demonstrating strong efficacy results, favorable safety/tolerability profile, and potential best-in-class dosing BIO89-100 has potential to be a leading DRUG FOR LIVER AND CARDIO-METABOLIC DISORDERS BIO89-100 DELIVERS ON THE PROMISE OF FGF21 FGF21 is a
Slide 38: Management Team
Management Team CEO, CCO experience Avanir, Medivation, J&J Commercial, strategy, and R&D experience 20+ years biopharma and R&D leadership in clinical development and medical affairs Ultragenyx, Medivation, Valeant, GSK 20 years of operations, BD, and strategy experience VP of strategy and transfor
Slide 39: Appendix
Appendix
Slide 40: BIO89-100 Significantly Improves Other Important Liver Biomarkers
BIO89-100 Significantly Improves Other Important Liver Biomarkers Despite Low Baseline Values PD Analysis Set; Pre-planned sensitivity analysis; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo *** AST Percent Change from Baseline at Week 13 * Q2W QW PRO-C3 Percent Change from Baseline
Slide 41: BIO89-100 Significantly Improves Key Lipid Markers
BIO89-100 Significantly Improves Key Lipid Markers Percentage Change from Baseline At Week 13 PD Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo ** * * * *** * Non-HDL QW Q2W LDL-c HDL-c QW Q2W QW Q2W
Slide 42: BIO89-100 Effect on Glycemic Control
BIO89-100 Effect on Glycemic Control Placebo 3mg QW 9mg QW 18mg QW 27mg QW 18mg Q2W 36mg Q2W Adiponectin % Change -4.3% 37.7%* 25.5%* 29.1%* 60.9%*** 23.1%* 24.1% Insulin& % Change 10.0% -8.5% -9.4% -22.5% -6.9% -39.7% -34.5% HbA1c (%) Absolute Change <0.1 0.6 0.1 0.1 -0.3 -0.1 0.5 No meaningful cha